⁹⁹ᵐTc-Maraciclatide Granted FDA Fast Track Designation for the Diagnosis of Superficial Peritoneal Endometriosis

London, UK, 2 July 2024. Serac Healthcare Limited, a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation to ^99mTc-maraciclatide as a diagnostic SPECT-CT agent for the visualisation and diagnosis of superficial peritoneal endometriosis in women of 16 years and older.